Rise Advisors’s Solid Biosciences SLDB Stock Holding History

Rise Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-95	Closed	-$352	–	1637
2025 Q1	$352	Buy	+95	New	+$407	﹤0.01%	1417

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Rise Advisors's SLDB Position: Q2 2025 in Review

Rise Advisors sold out of Solid Biosciences (SLDB) in Q2 2025, closing a stake of 95 shares — an estimated $352 sold.

Rise Advisors first reported a position in SLDB in Q1 2025 and held it in 1 quarter. The position peaked at $352 in Q1 2025. 114 funds tracked by Wall St. Rank hold SLDB as of Q2 2025.

Rise Advisors reported no remaining Solid Biosciences position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 95 Solid Biosciences shares in Q2 2025, an estimated $352.
Rise Advisors first reported a position in Solid Biosciences in Q1 2025 and held it in 1 quarter.
Rise Advisors's Solid Biosciences position peaked at $352 in Q1 2025.
114 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.